Your browser is no longer supported. Please, upgrade your browser.
ZYNE Zynerba Pharmaceuticals, Inc. monthly Stock Chart
ZYNE [NASD]
Zynerba Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own12.32% Shs Outstand23.40M Perf Week-9.05%
Market Cap143.96M Forward P/E- EPS next Y-1.60 Insider Trans0.00% Shs Float22.05M Perf Month52.16%
Income-36.10M PEG- EPS next Q-0.45 Inst Own38.30% Short Float26.11% Perf Quarter34.69%
Sales- P/S- EPS this Y42.60% Inst Trans-13.69% Short Ratio7.18 Perf Half Y-11.06%
Book/sh2.83 P/B1.99 EPS next Y13.70% ROA-40.80% Target Price- Perf Year-46.18%
Cash/sh2.37 P/C2.38 EPS next 5Y- ROE-46.30% 52W Range2.55 - 15.70 Perf YTD-6.79%
Dividend- P/FCF- EPS past 5Y-17.80% ROI- 52W High-65.15% Beta3.13
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low114.51% ATR0.51
Employees28 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)60.29 Volatility10.77% 11.52%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.10% Profit Margin- Rel Volume1.32 Prev Close5.63
ShortableYes LT Debt/Eq0.00 EarningsMar 09 Payout- Avg Volume801.62K Price5.47
Recom1.90 SMA2012.30% SMA5028.82% SMA200-11.32% Volume414,416 Change-2.84%
Dec-31-19Resumed ROTH Capital Buy $12
Oct-21-19Initiated Needham Buy $18
Apr-22-19Resumed Canaccord Genuity Buy
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Aug-15-17Upgrade ROTH Capital Neutral → Buy
Aug-15-17Downgrade Oppenheimer Outperform → Perform
Aug-15-17Downgrade Jefferies Buy → Hold
Aug-08-17Downgrade ROTH Capital Buy → Neutral
Aug-08-17Downgrade H.C. Wainwright Buy → Neutral $7
Aug-07-17Downgrade Piper Jaffray Overweight → Neutral
Aug-07-17Downgrade Maxim Group Buy → Hold
Aug-07-17Downgrade Cantor Fitzgerald Overweight → Neutral $28 → $4
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Feb-24-17Initiated Maxim Group Buy $32
Dec-22-16Initiated Cantor Fitzgerald Overweight $28
Dec-06-16Resumed Jefferies Buy
May-27-20 06:45AM  
May-26-20 06:52AM  
06:50AM  
May-25-20 11:30AM  
May-22-20 07:30AM  
May-21-20 08:00AM  
May-11-20 06:50AM  
Apr-28-20 01:01PM  
Apr-10-20 08:00AM  
Apr-02-20 05:45PM  
Mar-25-20 05:50PM  
Mar-10-20 06:50AM  
Mar-09-20 08:30AM  
Mar-05-20 08:30AM  
Mar-03-20 12:08PM  
12:07PM  
Mar-02-20 05:45PM  
Feb-26-20 08:49AM  
06:50AM  
Feb-25-20 11:21AM  
07:15AM  
Feb-20-20 08:30AM  
Feb-18-20 09:07AM  
Feb-10-20 05:45PM  
08:05AM  
Feb-03-20 05:45PM  
06:45AM  
Jan-31-20 03:45PM  
Jan-28-20 05:45PM  
Jan-14-20 05:50PM  
Jan-13-20 09:15AM  
06:50AM  
06:45AM  
Jan-08-20 10:38AM  
Dec-23-19 12:10PM  
10:12AM  
10:00AM  
09:36AM  
09:34AM  
Dec-22-19 09:23PM  
05:08PM  
02:21PM  
Dec-20-19 05:20PM  
04:01PM  
11:35AM  
10:00AM  
Dec-19-19 02:01PM  
01:32PM  
08:06AM  
Dec-18-19 04:16PM  
12:57PM  
12:28PM  
Dec-17-19 02:07PM  
01:43PM  
Dec-16-19 05:12PM  
11:19AM  
10:39AM  
07:05AM  
Dec-13-19 10:00AM  
Dec-12-19 10:23AM  
Dec-11-19 08:19PM  
04:31PM  
04:30PM  
Dec-09-19 10:08AM  
Dec-06-19 05:23PM  
11:30AM  
10:00AM  
09:22AM  
Dec-05-19 11:32AM  
Dec-04-19 04:00PM  
04:00PM  
03:51PM  
Dec-02-19 05:52PM  
10:15AM  
Nov-29-19 10:00AM  
Nov-27-19 03:00PM  
01:17PM  
Nov-26-19 08:36AM  
Nov-25-19 03:35PM  
10:34AM  
Nov-23-19 08:10AM  
Nov-22-19 11:55PM  
03:00PM  
10:35AM  
Nov-21-19 09:47AM  
05:00AM  
Nov-20-19 05:29PM  
03:10PM  
10:33AM  
Nov-19-19 10:58AM  
Nov-18-19 08:18PM  
10:32AM  
Nov-16-19 08:43AM  
Nov-15-19 03:00PM  
10:48AM  
10:04AM  
09:57AM  
Nov-13-19 06:45PM  
04:40PM  
03:37PM  
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.